Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: Thomas who wrote (90)	9/11/2003 11:48:06 AM
From: Thomas	Respond to of 671

This looks interesting. Anyone have a view as to the science/hype balance here? They are providing animal model data, which (as I understand it) does not translate perfectly into human in vivo results. Would be interested in any thought. Thanks in advance. Cheers, Thomas Press Release Source: Intradigm Corporation Intradigm to Present Targeted Systemic Delivery of siRNA At Nucleic Acid World Summit Thursday September 11, 10:35 am ET ROCKVILLE, Md., Sept. 11 /PRNewswire/ -- Intradigm Corp. announced today that its achievement of the first targeted delivery of siRNA therapeutic agents will be presented at the Nucleic Acid World Summit to be held in Boston, MA September 15-17, 2003. The company's TargeTran(TM) targeted delivery nanoparticle technology has now successfully been developed to target siRNA agents to neovasculature in tumors and other pathological tissues with unwanted angiogenesis. Intradigm will present results demonstrating efficacy in a clinically relevant animal disease model using intravenous administration of TargeTran-siRNA inhibiting VEGF pathway genes. The Nucleic Acid World Summit is sponsored by the Strategic Research Institute (www.srinstitute.com/naws). ADVERTISEMENT Intradigm has developed a portfolio of delivery systems for siRNA duplexes capable of efficient delivery into pathological tissues including human xenograft tumor models. Intradigm has been applying in vivo siRNA delivery for discovery and validation of novel cancer targets. With the expansion of its capabilities to include clinically viable systemic targeted delivery, the company is poised to initiate therapeutic development of siRNA-based anti- angiogenesis therapeutics. John Spears, Intradigm's CEO, commented, "We are very excited by the success of our TargeTran technology to address one of the key hurdles for siRNA to be considered as a therapeutic modality." Intradigm Corporation is a privately held Delaware corporation that is discovering and developing therapeutic products by applying proprietary in vivo RNAi delivery technologies. Intradigm's Efficacy-First(TM) Discovery and Disease-Control(TM) Validation methods are based on extensive nucleic acid delivery capabilities that, when combined with RNAi and animal disease models, provide rapid and effective discovery and validation of drug targets giving efficacy in clinically relevant disease models. Intradigm has a growing portfolio of novel targets for cancer therapeutics and associated candidate therapeutic agents including antibodies, small molecules, and siRNA. Investors include Emerging Technology Partners, Novartis Venture Fund and the State of Maryland's Business and Economic Development Department. Intradigm is located in the Association for Entrepreneurial Sciences Inc. facilities in Rockville, MD. -------------------------------------------------------------------------------- Source: Intradigm Corporation